title: Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.
abstract: The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages.
  
  
  
  Results from mandatory knowledge, attitude, and behavior surveys and voluntary patient surveys completed between June 2012 and June 2013 were analyzed, and responses to questions relating to compliance with birth control measures and understanding of safe-use messages are presented by patient risk category.
  
  
  
  In total, 73,645 patients were enrolled into the REMS programs for lenalidomide and thalidomide and completed mandatory surveys prior to medication dispense. Of these, 2790 (3.8%) completed an additional voluntary survey. Among voluntary survey participants, for all patient pregnancy risk categories, reported compliance with birth control requirements was above 90% when starting therapy and at follow-up. At the beginning of therapy, complete compliance was 96.3%; 3 months later it was 96.4%. Patient understanding of safe-use messages was very high in all pregnancy risk groups, notably for messages repeated at each physician visit. Overall, 98.2% of patients knew that lenalidomide and thalidomide could cause birth defects, which is part of the repeated educational messaging. In contrast, 87.1% recalled that unused product should be returned to their healthcare professional, which is not included in repeated messaging.
  
  
  
  The lenalidomide and thalidomide REMS programs enhance patient understanding of safe-use messages, resulting in high levels of compliance with the birth control precautions essential to prevent fetal exposure to these known and potential human teratogens. Overall compliance was maintained after 3 months of follow-up and throughout therapy.
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA.
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Brandenburg
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Bwire
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA.
authors.forename: John
authors.initials: J
authors.lastname: Freeman
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA.
authors.forename: Florence
authors.initials: F
authors.lastname: Houn
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA. psheehan@celgene.com.
authors.forename: Paul
authors.identifier: 0000-0001-6732-7284
authors.initials: P
authors.lastname: Sheehan
authors.affiliation: Celgene Corporation, 556 Morris Ave, Summit, NJ, 07901, USA.
authors.forename: Jerome B
authors.initials: JB
authors.lastname: Zeldis
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D032882:Comprehension; D003267:Contraception / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D010349:Patient Compliance; D010353:Patient Education as Topic / Q000379:methods*; D011247:Pregnancy; D000073938:Risk Evaluation and Mitigation; D011795:Surveys and Questionnaires; D013723:Teratogens / Q000633:toxicity; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D055815:Young Adult
chemical_list: D013723:Teratogens; D013792:Thalidomide; D000077269:Lenalidomide